Fenofibrate Combined With Ursodeoxycholic Acid

Phase 3Small molecule

Fenofibrate Combined With Ursodeoxycholic Acid is one of 33 small molecule programs targeting Primary Biliary Cholangitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Biliary CholangitisActive, not recruiting

Primary Biliary CholangitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Primary Biliary Cholangitis

#DrugCompanyPhaseTrials

Cellcept

Roche

Approved

1 2

Ocaliva

IIntercept Pharmaceuticals

Approved

2 3

Cyclosporin a

Novartis

Approved

1 4

Iqirvo

Ipsen

Phase 3

3 5

Lipaglyn

ZZydus Therapeutics Inc.

Phase 3

4 6

Rayos

RRoxane Laboratories

Phase 3

1 7

Olumiant

Eli Lilly

Phase 2

1 8

Seladelpar

Gilead

Phase 3

6 9

Bezafibrate

IIntercept Pharmaceuticals

Phase 3

1 10

Selincro

IIndivior Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Primary Biliary Cholangitis

NCT05751967

Q4 2035

Phase 3Recruiting

Primary Biliary Cholangitis

NCT06755541

Clinical

Trials by Indication[1]

Primary Biliary Cholangitis2 trials

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study

Recruiting·XXijing Hospital of Digestive Diseases·Phase 3·NCT06755541·150 enrolled

Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis

Recruiting·XXijing Hospital of Digestive Diseases·Phase 3·NCT05751967·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fenofibrate Combined With Ursodeoxycholic Acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fenofibrate Combined With Ursodeoxycholic Acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fenofibrate Combined With Ursodeoxycholic Acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xijing Hospital of Digestive Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: XXijing Hospital of Digestive Diseases

Fenofibrate Combined With Ursodeoxycholic Acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2035

Trials by Indication[1]

Primary Biliary Cholangitis2 trials

References

Drug Info

Quick Facts

Related News